Lyon Manufacturing Facility Returns To The Vectura Group
Chippenham, UK - 1 July: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading inhaled airways disease focused business, confirms that, as expected, the lease of its manufacturing facility and oral product business in Saint-Quentin-Fallavier, Lyon, France (together “the Facility”) to Aenova France SAS (“Aenova”) expired on 30 June 2016. The Facility transferred back to the Group upon expiry.
The Facility currently manufactures seven oral products for the Group’s partners. Five products use the GeomatrixTM family of technologies: Diclofenac-ratiopharm®-uno, Coruno®, ZYFLO CR®, Madopar® DR®/Prolopa®and Sular®, whilst Lodotra®/RAYOS® uses the GeoclockTM chronotechnology. The Facility also manufactures one other oral product, Triglide®, based on the Group’s solubilisation technology. In addition, there are currently a number of pipeline projects in development, including the first complex oral generic under the Group’s strategic partnership with Hikma Pharmaceuticals (SKP-1056). The Facility has cGMP status, with approvals from the European Medicines Agency, the FDA, ANVISA (Brazil) and KFDA (South Korea) amongst others.
A number of initiatives are underway to maximise the value of the Facility now that it has returned to the Group’s control, leveraging proven capabilities in multilayer tableting, oral technology innovation and the high quality manufacturing capacity at the Lyon site.
David Lescuyer, Executive Vice President, Oral Business, commented:
“We are very pleased that the Lyon facility returns to the Group at this exciting time. We have a strong high quality base with the return of the Facility and we are confident of growing the business and creating future value by working with existing and new partners and leveraging our proven innovation and technology.”
